Sana Biotechnology Inc vs S&P Global Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while S&P Global Inc trades at $431.27 (market cap $132.71B). The key difference: S&P Global Inc is far larger — about 151.9× Sana Biotechnology Inc's market cap, and S&P Global Inc pays a 0.87% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SPGI | |
|---|---|---|
Market Cap | $873.84M | $132.71B |
Sector | Health | Financials |
52-Week High | $5.92 | $534.79 |
52-Week Low | $2.68 | $370.42 |
Enterprise Value | $848.03M | $144.68B |
Dividend Yield | — | 0.87% |
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →